Overexpression of interleukin-18 protein reduces viability and induces apoptosis of tongue squamous cell carcinoma cells by activation of glycogen synthase kinase-3β signaling

Oncology Reports

Volumn 33, Issue 3, 2015, Pages 1049-1056

  Liu, Weiwei ^a   Hu, Min ^a   Wang, Yumei ^a   Sun, Baozhen ^a   Guo, Yu ^a   Xu, Zhimin ^a   Li, Jia ^a   Han, Bing ^a  

^a JILIN UNIVERSITY   (China)

Author keywords

Apoptosis; Gene expression; GSK 3 ; Interleukin 18; Tongue squamous cell carcinoma

Indexed keywords

CASPASE 3; CASPASE 7; CASPASE 9; COMPLEMENTARY DNA; CYCLIN A1; CYCLIN D1; CYTOCHROME C; GAMMA INTERFERON; GLYCOGEN SYNTHASE KINASE 3BETA; KENPAULLONE; LIPOCORTIN 5; MESSENGER RNA; PROPIDIUM IODIDE; RECOMBINANT INTERLEUKIN 18; GLYCOGEN SYNTHASE KINASE 3; GLYCOGEN SYNTHASE KINASE 3 BETA; INTERLEUKIN 18; INTERLEUKIN 18 PROTEIN, HUMAN;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL LINE; CANCER INHIBITION; CELL VIABILITY; CONTROLLED STUDY; CRL 1623 CELL LINE; DRUG TARGETING; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME DEGRADATION; ENZYME PHOSPHORYLATION; ENZYME REGULATION; EXPRESSION VECTOR; FLOW CYTOMETRY; GENE EXPRESSION; GENETIC TRANSFECTION; GIEMSA STAIN; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE TEST; IN VITRO STUDY; MOLECULAR CLONING; MTT ASSAY; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TONGUE CARCINOMA; UPREGULATION; WESTERN BLOTTING; BIOSYNTHESIS; CELL SURVIVAL; FLUORESCENT ANTIBODY TECHNIQUE; METABOLISM; PATHOLOGY; PHYSIOLOGY; REAL TIME POLYMERASE CHAIN REACTION; SQUAMOUS CELL CARCINOMA; TONGUE TUMOR;

APOPTOSIS; BLOTTING, WESTERN; CARCINOMA, SQUAMOUS CELL; CELL SURVIVAL; ENZYME ACTIVATION; FLOW CYTOMETRY; FLUORESCENT ANTIBODY TECHNIQUE; GLYCOGEN SYNTHASE KINASE 3; HUMANS; INTERLEUKIN-18; REAL-TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TONGUE NEOPLASMS; TRANSFECTION;

EID: 84921652725     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2015.3724     Document Type: Article

References (55)

1. World Health Organization and International Agency for Research on Cancer: World Cancer Report 2008. International Agency for Research on Cancer, Lyon-pp1-511, 2008.
2. Siegel R, Ma J, Zou Z and Jemal A: Cancer statistics, 2014. CA Cancer J Clin 64:9-29, 2014.
3. Bello IO, Soini Y and Salo T: Prognostic evaluation of oral tongue cancer: means, markers and perspectives (II). Oral Oncol 46:636-643, 2010.
4. Giudice FS, Dal Vechio AM, Abrahao AC, Sperandio FF and Pinto-Junior Ddos S: Different expression patterns of pAkt, NF-κB and cyclin D1 proteins during the invasion process of head and neck squamous cell carcinoma: an in vitro approach. J Oral Pathol Med 40:405-411, 2011.
5. Squarize CH, Castilho RM, Abrahao AC, Molinolo A, Lingen MW and Gutkind JS: PTEN deficiency contributes to the development and progression of head and neck cancer. Neoplasia 15:461-471, 2013.
6. Okamura H, Tsutsui H, Kashiwamura S, Yoshimoto T and Nakanishi K: Interleukin-18: a novel cytokine that augments both innate and acquired immunity. Adv Immunol 70:281-312, 1998.
7. Srivastava S, Salim N and Robertson MJ: Interleukin-18: biology and role in the immunotherapy of cancer. Curr Med Chem 17:3353-3357, 2010.
8. Tschoeke SK, Oberholzer A and Moldawer LL: Interleukin-18: a novel prognostic cytokine in bacteria-induced sepsis. Crit Care Med 34:1225-1233, 2006.
9. Lee HR, Yoon SY, Song SB, et al: Interleukin-18-mediated interferon-gamma secretion is regulated by thymosin beta 4 in human NK cells. Immunobiology 216:1155-1162, 2011.
10. Tse BW, Russell PJ, Lochner M, Forster I and Power CA: IL-18 inhibits growth of murine orthotopic prostate carcinomas via both adaptive and innate immune mechanisms. PloS One 6:e24241, 2011.
11. Tian H, Shi G, Yang G, et al: Cellular immunotherapy using irradiated lung cancer cell vaccine co-expressing GM-CSF and IL-18 can induce significant antitumor effects. BMC Cancer 14:48, 2014.
12. Wong JL, Muthuswamy R, Bartlett DL and Kalinski P: IL-18-based combinatorial adjuvants promote the intranodal production of CCL19 by NK cells and dendritic cells of cancer patients. Oncoimmunology 2:e26245, 2013.
13. Korur S, Huber RM, Sivasankaran B, et al: GSK3beta regulates differentiation and growth arrest in glioblastoma. PloS One 4:e7443, 2009.
14. Atkins RJ, Dimou J, Paradiso L, et al: Regulation of glycogen synthase kinase-3 beta (GSK-3β) by the Akt pathway in gliomas. J Clin Neurosci 19:1558-1563, 2012.
15. Grimes CA and Jope RS: The multifaceted roles of glycogen synthase kinase 3beta in cellular signaling. Prog Neurobiol 65:391-426, 2001.
16. Takahashi-Yanaga F: Activator or inhibitor? GSK-3 as a new drug target. Biochem Pharmacol 86:191-199, 2013.
17. Kim M, Datta A, Brakeman P, Yu W and Mostov KE: Polarity proteins PAR6 and aPKC regulate cell death through GSK-3beta in 3D epithelial morphogenesis. J Cell Sci 120:2309-2317, 2007.
18. Doble BW and Woodgett JR: GSK-3: tricks of the trade for a multi-tasking kinase. J Cell Sci 116:1175-1186, 2003.
19. Yoshimura T, Kawano Y, Arimura N, Kawabata S, Kikuchi A and Kaibuchi K: GSK-3beta regulates phosphorylation of CRMP-2 and neuronal polarity. Cell 120:137-149, 2005.
20. Liu C, Li Y, Semenov M, et al: Control of beta-catenin phosphorylation/degradation by a dual-kinase mechanism. Cell 108:837-847, 2002.
21. Wu G and He X: Threonine 41 in beta-catenin serves as a key phosphorylation relay residue in beta-catenin degradation. Biochemistry 45:5319-5323, 2006.
22. Qu Z, Sun D and Young W: Lithium promotes neural precursor cell proliferation: evidence for the involvement of the non-canonical GSK-3β-NF-AT signaling. Cell Biosci 1:18, 2011.
23. Zhang X, Chen T, Zhang J, et al: Notch1 promotes glioma cell migration and invasion by stimulating β-catenin and NF-κB signaling via AKT activation. Cancer Sci 103:181-190, 2012.
24. Lu W and Li Y: Salinomycin suppresses LRP6 expression and inhibits both Wnt/β-catenin and mTORC1 signaling in breast and prostate cancer cells. J Cell Biochem 155:1799-1807, 2014.
25. Mishra R: Glycogen synthase kinase 3 beta: can it be a target for oral cancer. Mol Cancer 9:144, 2010.
26. Wen W, Ding J, Sun W, et al: Cyclin G1-mediated epithelialmesenchymal transition via phosphoinositide 3-kinase/Akt signaling facilitates liver cancer progression. Hepatology 55:1787-1798, 2012.
27. Liu W, Han B, Sun B, Gao Y, Huang Y and Hu M: Overexpression of interleukin-18 induces growth inhibition, apoptosis and gene expression changes in a human tongue squamous cell carcinoma cell line. J Int Med Res 40:537-544, 2012.
28. Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2 (-Delta Delta C (T)) method. Methods 25:402-408, 2001.
29. Zheng JN, Pei DS, Sun FH, et al: Potent antitumor efficacy of interleukin-18 delivered by conditionally replicative adenovirus vector in renal cell carcinoma-bearing nude mice via inhibition of angiogenesis. Cancer Biol Ther 8:599-606, 2009.
30. Mo C, Dai Y, Kang N, Cui L and He W: Ectopic expression of human MutS homologue 2 on renal carcinoma cells is induced by oxidative stress with interleukin-18 promotion via p38 mitogen-activated protein kinase (MAPK) and c-Jun. N-terminal kinase (JNK) signaling pathways. J Biol Chem 287:19242-19254, 2012.
31. Nilkaeo A and Bhuvanath S: Role of interleukin-18 in modulation of oral carcinoma cell proliferation. Mediators Inflamm 2006:67120, 2006.
32. Shiratori I, Suzuki Y, Oshiumi H, et al: Recombinant interleukin-12 and interleukin-18 antitumor therapy in a guinea-pig hepatoma cell implant model. Cancer Sci 98:1936-1942, 2007.
33. Wang J, Kobayashi Y, Sato A, Kobayashi E and Murakami T: Synergistic anti-tumor effect by combinatorial gene-gun therapy using IL-23 and IL-18 cDNA. J Dermatol Sci 36:66-68, 2004.
34. Chaudhry UI, Kingham TP, Plitas G, Katz SC, Raab JR and DeMatteo RP: Combined stimulation with interleukin-18 and CpG induces murine natural killer dendritic cells to produce IFN-gamma and inhibit tumor growth. Cancer Res 66:10497-10504, 2006.
35. Xu TP, Shen H, Liu LX and Shu YQ: Plumbagin from Plumbago Zeylanica L induces apoptosis in human non-small cell lung cancer cell lines through NF-κB inactivation. Asian Pac J Cancer Prev 14:2325-2331, 2013.
36. Hosotani Y, Kashiwamura S, Kimura-Shimmyo A, et al: Interleukin-18 prevents apoptosis via PI3K/Akt pathway in normal human keratinocytes. J Dermatol 35:514-524, 2008.
37. Chandrasekar B, Vemula K, Surabhi RM, et al: Activation of intrinsic and extrinsic proapoptotic signaling pathways in interleukin-18-mediated human cardiac endothelial cell death. J Biol Chem 279:20221-20233, 2004.
38. John T, Kohl B, Mobasheri A, Ertel W and Shakibaei M: Interleukin-18 induces apoptosis in human articular chondrocytes. Histol Histopathol 22:469-482, 2007.
39. Jin H, Liu AD, Holmberg L, et al: The role of sulfur dioxide in the regulation of mitochondrion-related cardiomyocyte apoptosis in rats with isopropylarterenol-induced myocardial injury. Int J Mol Sci 14:10465-10482, 2013.
40. Broughton BR, Reutens DC and Sobey CG: Apoptotic mechanisms after cerebral ischemia. Stroke 40:e331-339, 2009.
41. Schoenborn JR and Wilson CB: Regulation of interferon-gamma during innate and adaptive immune responses. Adv Immun 96:41-101, 2007.
42. Xu G, Li Y, Yoshimoto K, et al: 2, 3, 7, 8-Tetrachlorodibenzo-pdioxin stimulates proliferation of HAPI microglia by affecting the Akt/GSK-3β/cyclin D1 signaling pathway. Toxicol Lett 224:362-370, 2014.
43. Bienvenu F, Jirawatnotai S, Elias JE, et al: Transcriptional role of cyclin D1 in development revealed by a genetic-proteomic screen. Nature 463:374-378, 2010.
44. Malumbres M and Barbacid M: Cell cycle, CDKs and cancer: a changing paradigm. Nat Rev Cancer 9:153-166, 2009.
45. Motokura T, Bloom T, Kim HG, et al: A novel cyclin encoded by a bcl1-linked candidate oncogene. Nature 350:512-515, 1991.
46. Witzel II, Koh LF and Perkins ND: Regulation of cyclin D1 gene expression. Biochem Soc Trans 38:217-222, 2010.
47. Beurel E and Jope RS: The paradoxical pro- and anti-apoptotic actions of GSK3 in the intrinsic and extrinsic apoptosis signaling pathways. Prog Neurobiol 79:173-189, 2006.
48. Hoeflich KP, Luo J, Rubie EA, Tsao MS, Jin O and Woodgett JR: Requirement for glycogen synthase kinase-3beta in cell survival and NF-kappaB activation. Nature 406:86-90, 2000.
49. Belkhiri A, Dar AA, Zaika A, Kelley M and El-Rifai W: T-Darpp promotes cancer cell survival by up-regulation of Bcl2 through Akt-dependent mechanism. Cancer Res 68:395-403, 2008.
50. Zhang Q, Fu H, Zhang H, et al: Hydrogen sulfide preconditioning protects rat liver against ischemia/reperfusion injury by activating Akt-GSK-3β signaling and inhibiting mitochondrial permeability transition. PLoS One 8:e74422, 2013.
51. Tan J, Zhuang L, Leong HS, Iyer NG, Liu ET and Yu Q: Pharmacologic modulation of glycogen synthase kinase-3beta promotes p53-dependent apoptosis through a direct Bax-mediated mitochondrial pathway in colorectal cancer cells. Cancer Res 65:9012-9020, 2005.
52. Lee Y, Dominy JE, Choi YJ, et al: Cyclin D1-Cdk4 controls glucose metabolism independently of cell cycle progression. Nature 510:547-551, 2014.
53. Takahashi-Yanaga F and Sasaguri T: GSK-3beta regulates cyclin D1 expression: a new target for chemotherapy. Cell Signal 20:581-589, 2008.
54. Ye X, Guo Y, Zhang Q, et al: βKlotho suppresses tumor growth in hepatocellular carcinoma by regulating Akt/GSK-3β/cyclin D1 signaling pathway. PLoS One 8:e55615, 2013.
55. Blanco J, Mulero M, Domingo JL and Sanchez DJ: Perinatal exposure to BDE-99 causes decreased protein levels of cyclin D1 via GSK3β activation and increased ROS production in rat pup livers. Toxicol Sci 137:491-498, 2014.